Pay in 4 interest-free payments of $6.31 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
The relevant Phase II clinical data for Survodutide was recently published in the New England Journal of Medicine
This is the IP architecture of a bio-better: the modification both improves the clinical product and generates new patent claims that do not depend on the original molecules patent estate
This raises ethical questions about equitable treatment options, especially when lifestyle modifications and other pharmacological alternatives may offer sustainable benefits at lower costs
The clinical and biochemical features of the 3 patients reported here demonstrate that at least certain BBOX1 variants cause a significant phenotype affecting neuromuscular and psycho-mental development and functioning
Finally, in a meta-analysis of randomized trials on the use of vitamin B supplements for homocysteine reduction, folate supplementation had no significant effect on the 5-year incidence of CHD
